Connor, Clark & Lunn Investment Management (CC&L)
ADMS

Connor, Clark & Lunn Investment Management (CC&L)’s Adamas Pharmaceuticals ADMS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-24,595
Closed -$106K – 1139
2020
Q4 		$106K Buy
24,595
+8,165
+50% +$34.9K ﹤0.01% 857
2020
Q3 		$68K Buy
16,430
+3,176
+24% +$12.3K ﹤0.01% 889
2020
Q2 		$34K Sell
13,254
-30,712
-70% -$90.3K ﹤0.01% 990
2020
Q1 		$127K Buy
43,966
+20,066
+84% +$89.9K ﹤0.01% 911
2019
Q4 		$91K Buy
+23,900
New +$114K ﹤0.01% 882
2016
Q1 		– Sell
-13,600
Closed -$385K – 928
2015
Q4 		$385K Buy
13,600
+3,000
+28% +$50.5K ﹤0.01% 591
2015
Q3 		$177K Sell
10,600
-400
-4% -$9.1K ﹤0.01% 652
2015
Q2 		$288K Hold
11,000
– – ﹤0.01% 503
2015
Q1 		$192K Buy
+11,000
New +$188K ﹤0.01% 506

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ADMS Position: Q1 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Adamas Pharmaceuticals (ADMS) in Q1 2021, closing a stake of 24,595 shares — an estimated $106K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ADMS in Q1 2015 and held it in 9 quarters. The position peaked at $385K in Q4 2015. 73 funds tracked by Wall St. Rank hold ADMS as of Q1 2021.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Adamas Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 24,595 Adamas Pharmaceuticals shares in Q1 2021, an estimated $106K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Adamas Pharmaceuticals in Q1 2015 and held it in 9 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Adamas Pharmaceuticals position peaked at $385K in Q4 2015.
  • 73 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2021, filed 13 May 2021.